396 related articles for article (PubMed ID: 20538934)
1. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
2. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
3. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
4. Patent watch.
Harrison C
Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
[No Abstract] [Full Text] [Related]
5. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
6. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
[No Abstract] [Full Text] [Related]
8. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
9. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
10. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
11. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
12. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
13. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
14. AIDS drugs. Brazil, Thailand override big pharma patents.
Cohen J
Science; 2007 May; 316(5826):816. PubMed ID: 17495145
[No Abstract] [Full Text] [Related]
15. Patent reform in the US: what's at stake for pharmaceutical innovation?
Yancey A; Stewart CN
Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
[TBL] [Abstract][Full Text] [Related]
16. [Parallel import of drugs for better and for worse].
Krabbe U
Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
[No Abstract] [Full Text] [Related]
17. The people vs patents.
New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
[No Abstract] [Full Text] [Related]
18. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
19. Sending pharma better signals.
Avorn J
Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
[No Abstract] [Full Text] [Related]
20. Patent watch: the patent cliff steepens.
Harrison C
Nat Rev Drug Discov; 2011 Jan; 10(1):12-3. PubMed ID: 21193859
[No Abstract] [Full Text] [Related]
[Next] [New Search]